Ind Swift Laboratories Limited (ISLL) has made significant progress in its share listing process following a recent scheme of amalgamation. The company has received a crucial approval from the National Stock Exchange of India (NSE) and is awaiting final clearance from the Bombay Stock Exchange (BSE) to complete the listing of newly allotted equity shares.

Key Developments

• NSE Approval: On October 10, 2025, ISLL received listing approval from NSE for equity shares allotted to eligible shareholders of Ind-Swift Limited under the approved scheme of amalgamation.
• BSE Approval: The approval from BSE is currently pending and expected shortly, as per the company's latest update.
• Application Timeline: ISLL filed listing applications with both NSE and BSE on September 12, 2025.

Next Steps

Upon receiving BSE approval, ISLL plans to:

1. Credit shares to shareholders' Demat accounts
2. Apply for trading approval

It's important to note that shareholders will only be able to trade the newly allotted equity shares after trading approval is granted by both exchanges.

Corporate Communication

In an update dated November 4, 2025, Pardeep Verma, VP-Corporate Affairs & Company Secretary of ISLL, provided additional details:

• The company has submitted all required documents and clarifications to BSE.
• ISLL is in regular communication with BSE to expedite the approval process.
• The BSE approval is reportedly under final review.

Implications for Shareholders

Shareholders of Ind-Swift Limited who are eligible for equity shares in ISLL under the amalgamation scheme should be aware that:

• The process is nearing completion with NSE approval secured.
• Trading of new shares is contingent on both NSE and BSE approvals.
• ISLL is actively working to finalize the process and will inform shareholders of further developments.

This corporate action represents a significant step for Ind-Swift Laboratories Limited and affected shareholders. The company's proactive communication demonstrates its commitment to transparency and regulatory compliance throughout this process.

Ind Swift Laboratories has made a strategic move into the sports and entertainment sector by approving the incorporation of a 50:50 joint venture to participate in the inaugural Chandigarh Premier League (CPL). The company's investment committee gave the green light for this venture during a meeting held on September 12, 2025.

Joint Venture Details

The joint venture will be structured as a Limited Liability Partnership (LLP) between Ind Swift Laboratories and Mr. Nikhil Goel. Key points of the venture include:

• Equal partnership: 50% contribution from each party
• Company's investment: Up to Rs. 2.00 crores
• Primary activities: Sponsorship/ownership of a cricket team in the CPL and participation in cricket tournaments and other sports-related initiatives

Strategic Rationale

Ind Swift Laboratories cited two main reasons for this investment:

1. The significant fan following and commercial potential of cricket in India
2. The strategic opportunity to associate with the CPL at its inception, enabling the company to build a strong presence in the sports and entertainment ecosystem

Regulatory Compliance

The company has emphasized that the investment does not constitute a related party transaction. The incorporation of the joint venture is subject to the completion of statutory and regulatory formalities.

Market Impact

This move represents a diversification for Ind Swift Laboratories, traditionally known for its pharmaceutical operations. By entering the sports entertainment sector, the company is positioning itself to tap into the cricket market in India.

Future Prospects

While the immediate focus is on the Chandigarh Premier League, the joint venture's scope includes participation in other cricket tournaments and sports-related initiatives. This suggests a long-term commitment to building a presence in the sports sector.

The success of this venture could open new revenue streams for Ind Swift Laboratories and potentially enhance its brand visibility beyond the pharmaceutical industry.